Navega Therapeutics
San Diego, US · Delaware corporation
Navega Therapeutics develops gene therapies using zinc-finger and CRISPR-based epigenome regulation to control gene expression. The company works in the biotech and gene therapy space.
Founders & leadership
FA
Fernando AlemanCo-founder
AM
Ana MorenoCo-founder
RS
Randy SocolExecutive
Funding
SEC filings, press & company announcements$1.3M disclosed across 1 of 2 rounds · 2024–2026
- Undisclosed amountSeries ANov 2024Source ↗
▶$1.3MraisedJan 2026 · 8 investors · BiotechnologyRule 506(b)
▶$1.3MraisedJan 2026 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Randy SocolExecutive Officer
- Fernando AlemanExecutive Officer, Director
- Ana MorenoExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1.3M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 7
by search overlapAbeona Therapeutics9 shared keywordsAbeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases with high unmet need, including its approved product ZEVASKYN and its lead PSMA-targeted T cell therapy ABO-701 for advanced prostate cancer. It uses ex vivo gene therapy, viral vector, and synthetic immune receptor T cell (SIR-T) technologies to serve patients with genetic diseases and solid tumors.
Bioworld8 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Nava Therapeutics8 shared keywordsNava develops lipid nanoparticles (LNPs) designed to deliver RNA therapeutics to specific organs and cellular targets for genetic medicine applications. The company focuses on addressing unmet medical needs across a range of RNA therapeutic treatments.
Neurona Therapeutics8 shared keywordsNeurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter>
<parameter name="founders">[]
Averna Therapeutics8 shared keywordsAverna Therapeutics is a biotechnology company developing therapeutics. The page is a team bio profiling its CEO and board member.
Transcode Therapeutics8 shared keywordsTransCode Therapeutics is a biotechnology company developing targeted RNA therapeutics to treat various cancers by modulating microRNAs involved in tumor progression and metastasis.
Orna7 shared keywordsOrna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications. The company leverages proprietary drug development expertise in oRNA and LNP technology platforms.
Companies competing with Navega Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 7 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $400K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $275.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $624.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $288.3K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Navega Therapeutics do?
- Navega Therapeutics develops gene therapies using zinc-finger and CRISPR-based epigenome regulation to control gene expression. The company works in the biotech and gene therapy space.
- Who founded Navega Therapeutics?
- Navega Therapeutics was founded by Fernando Aleman, Ana Moreno.
- How much funding has Navega Therapeutics raised?
- Navega Therapeutics has disclosed $1.3M raised across 1 of its 2 known rounds.
- Where is Navega Therapeutics headquartered?
- Navega Therapeutics is headquartered in San Diego, US.